Scinus Group, a Utrecht-based biotech company, has raised €3 million in a strategic investment round led by Myosotis Investments, with participation from Demcon Innovation Fund. The funding will accelerate the global rollout of its Osilaris™ cell expansion platform, a GMP-compliant, automated bioreactor designed to overcome manufacturing bottlenecks and reduce costs in cell therapy production.
Cell therapy manufacturing faces challenges in scalability, consistency, and high production costs. Scinus addresses these issues with the Osilaris™ system, a closed, automated, and dynamic platform for efficient stem cell cultivation and therapy development, including CAR-T, CAR-TCR, and MSC therapies.
The platform is already deployed by academic ATMP manufacturers and CDMOs across Europe, enabling streamlined cell expansion for research and clinical applications.
In leadership updates, Dr. Erik Vossenaar will transition to Executive Director and CEO to guide the company’s next growth phase.
The new funding will be used to enhance organizational maturity and expand commercial operations in key markets, supporting Scinus’s mission to make scalable, high-quality cell therapy production accessible globally.
